Inivata is a global clinical cancer genomics company utilising a proprietary, industry-leading liquid biopsy platform to transform patient care.  

Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment.

Inivata's InVision™ liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with a select multi-gene panel to provide clinically actionable information to clinicians.

 

£31.5m raised in Series A funding, January 2016

 

Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies.  The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK.

 

More from our Portfolio

Congenica

HEALTHCARE GROWTH
View company profile congenica.com

CMR Surgical

HEALTHCARE GROWTH
View company profile cmrsurgical.com

Carrick Therapeutics

HEALTHCARE GROWTH
View company profile carricktherapeutics.com

Fluidic Analytics

HEALTHCARE GROWTH
View company profile www.fluidicanalytics.com